- Home
- MIRM vs LTH Comparison
MIRM vs LTH Comparison
Compare MIRM & LTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- LTH
- Stock Information
- Founded
- MIRM 2018
- LTH 1992
- Country
- MIRM United States
- LTH United States
- Employees
- MIRM N/A
- LTH N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- LTH Hotels/Resorts
- Sector
- MIRM Health Care
- LTH Consumer Discretionary
- Exchange
- MIRM Nasdaq
- LTH Nasdaq
- Market Cap
- MIRM 1.9B
- LTH N/A
- IPO Year
- MIRM 2019
- LTH 2021
- Fundamental
- Price
- MIRM $39.10
- LTH $31.31
- Analyst Decision
- MIRM Strong Buy
- LTH Buy
- Analyst Count
- MIRM 11
- LTH 12
- Target Price
- MIRM $58.55
- LTH $33.21
- AVG Volume (30 Days)
- MIRM 476.2K
- LTH 2.2M
- Earning Date
- MIRM 05-07-2025
- LTH 05-08-2025
- Dividend Yield
- MIRM N/A
- LTH N/A
- EPS Growth
- MIRM N/A
- LTH 100.00
- EPS
- MIRM N/A
- LTH 0.74
- Revenue
- MIRM $336,888,000.00
- LTH $2,620,995,000.00
- Revenue This Year
- MIRM $29.51
- LTH $14.12
- Revenue Next Year
- MIRM $20.27
- LTH $11.10
- P/E Ratio
- MIRM N/A
- LTH $42.31
- Revenue Growth
- MIRM 80.76
- LTH 18.24
- 52 Week Low
- MIRM $23.14
- LTH $12.34
- 52 Week High
- MIRM $54.23
- LTH $33.64
- Technical
- Relative Strength Index (RSI)
- MIRM 34.64
- LTH 54.08
- Support Level
- MIRM $37.83
- LTH $30.87
- Resistance Level
- MIRM $40.32
- LTH $32.27
- Average True Range (ATR)
- MIRM 2.47
- LTH 1.63
- MACD
- MIRM -0.33
- LTH 0.18
- Stochastic Oscillator
- MIRM 25.14
- LTH 83.84
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.